A Danish study analyzing data from over 7,700 rheumatoid arthritis (RA) patients has revealed significant differences in how men and women respond to anti-TNF therapy, a common treatment for the autoimmune disease. The research, conducted using the DANBIO registry, indicates that treatment outcomes vary based on sex, even when disease activity is comparable at the start of therapy.
The study, which followed patients initiating anti-TNF treatment between January 2003 and June 2008, examined both early-stage (less than two years duration) and established RA. Researchers found that 328 women and 148 men were diagnosed with early RA, although 1245 women and 408 men had established RA at the beginning of treatment. Despite similar levels of disease activity, measured by the 28-joint Disease Activity Score (DAS28), men and women exhibited differing responses over a 48-month follow-up period.
The findings, recently highlighted by Nature, build on earlier research identifying predictors of both initial non-response and loss of response to anti-TNF medications. A separate analysis published by Medscape Medical News in February 2026 indicated demographic and biochemical factors play a role in treatment success. The DANBIO registry has been instrumental in identifying these patterns.
Researchers utilized a generalized estimating equations (GEE) model to assess European League Against Rheumatism (EULAR) responses, adjusting for factors such as age, disease duration, and the use of other medications like methotrexate and prednisolone. The analysis revealed consistent sex-based differences in treatment response across both early and established RA cohorts.
The study’s authors, including Damini Jawaheer of the Children’s Hospital Oakland Research Institute and Jørn Olsen of the University of California Los Angeles and the University of Aarhus, did not elaborate on the underlying mechanisms driving these differences. The research, originally published in The Journal of Rheumatology in 2012, continues to inform current investigations into personalized treatment strategies for RA.
A 2013 publication in PMC further investigated sex differences in response to anti-TNF therapy, focusing on early versus established rheumatoid arthritis. The study’s findings underscore the need for a more nuanced understanding of how biological therapies affect men and women differently.
As of February 24, 2026, the DANBIO registry remains active, continuing to collect data on RA patients in Denmark. Researchers have not yet released further analysis detailing the specific biochemical factors contributing to the observed sex-based variations in anti-TNF response.
